» Articles » PMID: 33741915

Clonal Architecture in Mesothelioma is Prognostic and Shapes the Tumour Microenvironment

Abstract

Malignant Pleural Mesothelioma (MPM) is typically diagnosed 20-50 years after exposure to asbestos and evolves along an unknown evolutionary trajectory. To elucidate this path, we conducted multi-regional exome sequencing of 90 tumour samples from 22 MPMs acquired at surgery. Here we show that exomic intratumour heterogeneity varies widely across the cohort. Phylogenetic tree topology ranges from linear to highly branched, reflecting a steep gradient of genomic instability. Using transfer learning, we detect repeated evolution, resolving 5 clusters that are prognostic, with temporally ordered clonal drivers. BAP1/-3p21 and FBXW7/-chr4 events are always early clonal. In contrast, NF2/-22q events, leading to Hippo pathway inactivation are predominantly late clonal, positively selected, and when subclonal, exhibit parallel evolution indicating an evolutionary constraint. Very late somatic alteration of NF2/22q occurred in one patient 12 years after surgery. Clonal architecture and evolutionary clusters dictate MPM inflammation and immune evasion. These results reveal potentially drugable evolutionary bottlenecking in MPM, and an impact of clonal architecture on shaping the immune landscape, with potential to dictate the clinical response to immune checkpoint inhibition.

Citing Articles

Mesothelioma cell heterogeneity identified by single cell RNA sequencing.

Wu L, Wang Z, Zia A, Kelley S, de Perrot M Sci Rep. 2025; 15(1):8725.

PMID: 40082554 PMC: 11906801. DOI: 10.1038/s41598-025-92542-3.


The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes.

Torricelli F, Spada F, Bishop C, Todd K, Nonaka D, Petrov N J Transl Med. 2025; 23(1):208.

PMID: 39980060 PMC: 11844119. DOI: 10.1186/s12967-025-06193-z.


Editorial: Asbestos and disease genomics: is mesothelioma a genomic paradigm?.

Jaurand M, Murphy F, Felley-Bosco E Front Toxicol. 2025; 6():1536344.

PMID: 39831064 PMC: 11739162. DOI: 10.3389/ftox.2024.1536344.


A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

Zhang M, Bzura A, Baitei E, Zhou Z, Spicer J, Poile C Nat Commun. 2024; 15(1):7187.

PMID: 39168966 PMC: 11339264. DOI: 10.1038/s41467-024-49842-5.


Mesothelioma: molecular pathology and biomarkers.

Hung Y Pathologie (Heidelb). 2024; 45(5):316-323.

PMID: 39110166 DOI: 10.1007/s00292-024-01344-3.


References
1.
Wagner J, SLEGGS C, Marchand P . Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960; 17:260-71. PMC: 1038078. DOI: 10.1136/oem.17.4.260. View

2.
Odgerel C, Takahashi K, Sorahan T, Driscoll T, Fitzmaurice C, Yoko-O M . Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017; 74(12):851-858. PMC: 5740549. DOI: 10.1136/oemed-2017-104298. View

3.
Kircheva D, Husain A, Watson S, Kindler H, Durkin A, Vigneswaran W . Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016; 49(6):1642-7. DOI: 10.1093/ejcts/ezv422. View

4.
Yap T, Aerts J, Popat S, Fennell D . Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017; 17(8):475-488. DOI: 10.1038/nrc.2017.42. View

5.
Bott M, Brevet M, Taylor B, Shimizu S, Ito T, Wang L . The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011; 43(7):668-72. PMC: 4643098. DOI: 10.1038/ng.855. View